Clinical trial
A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel…
NCT02826161 · Sumitomo Pharma America, Inc., Industry · Terminated
Key facts
| NCT number | NCT02826161 |
|---|---|
| Title | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer |
| Official title | A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer |
| Acronym | CanStem43L |
| Lead sponsor | Sumitomo Pharma America, Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Napabucasin, Paclitaxel |
| Enrollment | 4 |
| Start date | Nov 1, 2016 |
| Primary completion | Apr 24, 2017 |
| Completion | Apr 24, 2017 |
| First posted | Jul 7, 2016 |
| Last update posted | Nov 15, 2023 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: